INCYTE CORP - 8-K Filing
Incyte Corporation agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion upfront with up to $750 million in additional payments tied to sales milestones, expanding its hematology portfolio into bleeding disorders. The acquisition includes VGA039, a Phase 3 monoclonal antibody targeting Protein S for von Willebrand disease (VWD), which has received Breakthrough Therapy and Fast Track designations from the FDA. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $INCY